Department of Neurology, Seoul National University Hospital, Seoul, Korea
Multiple sclerosis is an inflammatory demyelinating disease of central nervous system caused by
various autoimmune responses. Recent studies about pathophysiology of multiple sclerosis have
led to development of various disease modifying drugs. Monoclonal antibodies are commonly used
in treatment of autoimmune diseases and several cancers, but recently diverse clinical researches
investigated about its effectiveness in multiple sclerosis. Monoclonal antibody belongs to targeted
therapy with highly specific immune-modulatory property, so it may offer considerable effect over
other conventional therapies for multiple sclerosis. Further studies are needed about therapeutic effect
and safety of monoclonal antibodies in multiple sclerosis.
Journal of Multiple Sclerosis 3(2):47-50, 2012
